Beijing, China
Silexon AI, founded in 2018, is leveraging advancements in Artificial Intelligence and Machine Learning to revolutionize drug discovery and life sciences. With its headquarters in China, the company operates at the intersection of AI, Biotechnology, and data-driven research, adhering to its slogan, "AI Empowers Drug Discovery and Life Sciences."
The company's core asset is its proprietary AI/ML platform designed to drive collaboration across the life sciences sector, aiming to expedite the development of innovative drugs that address unmet medical needs. Silexon AI's platform not only facilitates research but also accelerates the process of drug innovation.
Receiving a Series A investment on 17 October 2019 from prominent investors including MSA Capital, Shengding Equity Investment Fund, and Prosperico Ventures, Silexon AI is poised for strategic growth and continued influence in its field. Venture capitalists may see substantial potential in their technological and collaborative approach.
